BioSpace News Archive

Mallinckrodt plc announced two scientific posters to be presented on the disease progression and treatment paradigms for patients with hepatorenal syndrome involving rapid reduction in kidney function1 at the European Association for the Study of the Liver 2022 International Liver Congress, taking place June 22 – 26 in London, UK.

Cingulate Inc. today announced completion of the formulation study for its third asset, CTx-2103, for the management of anxiety-related disorders.

uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced safety and biomarker data from 10 patients enrolled in the low-dose cohort of the ongoing Phase I/II clinical trial of AMT-130 for the treatment of Huntington’s disease.

Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced the appointment of Douglas M. Fambrough, III, Ph.D. to its board of directors.

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced the appointment of Carrie Melvin as Chief Operating Officer, a newly created position at the company.

RedHill Biopharma Announces Q1/22 Highlights: On Track for Positive Cash from Operations in H2/22.

Open-label study will evaluate the potential for DISC-0974, a first-in-class, anti-HJV (hemojuvelin) monoclonal antibody to improve anemia in myelofibrosis patients.

Positive effects on oxygenation observed with the 2.5 mg/kg dose at the end of the exercise interval.

Artios Pharma Limited (Artios), a clinical-stage biotech company pioneering the development of novel small molecule therapeutics that target the DNA damage response (“DDR”) process in order to treat patients suffering from a broad range of cancers, announces the appointment of Samantha Truex, a seasoned biotechnology executive, to its Board of Directors, effective June 15th, 2022.

Cullinan Oncology, Inc. (Cullinan Oncology) (Nasdaq: CGEM) a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for patients with cancer, today announced the completion of its agreement with Taiho Pharmaceutical Co., Ltd. (Taiho) signed in May 2022.